This suggests a potential positive feedback loop where KRAS/TP53 mutations reshape the TME of LUAD, inducing the enrichment of IS MUT neutrophils during tumor evolution, while RHOV, as an IS MUT neutrophil-related gene, conversely contributes to tumor progression. The gene discussed is RHOV; the disease is neoplasm.